5-Brom-salicylsaeure-(3,4-dibrom-anilid) | 4214-52-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-Brom-salicylsaeure-(3,4-dibrom-anilid)
• 英文别名: 3',4',5-Tribrom-salicylanilid；5-bromo-N-(3,4-dibromophenyl)-2-hydroxybenzamide
• CAS: 4214-52-2
• 化学式: C₁₃H₈Br₃NO₂
• 分子量: 449.924
• InChiKey: MSCWBYUQVSKMAT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• CATIONIC STEROIDAL ANTIMICROBIAL PRODRUG COMPOSITIONS AND USES THEREOF
  申请人：Savage Paul B.

  公开号：US20160096864A1

  公开（公告）日：2016-04-07

  Prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, or polymorphs thereof include a pharmaceutically and/or diagnostically active cationic steroidal antimicrobial (hereinafter “CSA”) compound or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof, and one or more cleavable groups (C.G.). Some embodiments include a CSA compound prepared in an inactive or less active form and that is capable of conversion to a fully active form upon administration to a subject, upon preparation of a pharmaceutical formulation containing the CSA composition, and/or upon exposure to physiological conditions. Pharmaceutical compositions include the prodrug or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof and one or more pharmaceutically acceptable excipients. Methods of treatment of bacterial infections in a patient in need utilize prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, polymorphs thereof and/or the pharmaceutical compositions described herein.

  前药或药学上可接受的盐、立体异构体、溶剂化物或其多晶体包括一种药学上和/或诊断上活性的阳离子类固醇抗微生物化合物（以下简称“CSA”）化合物或药学上可接受的盐、立体异构体、溶剂化物或其多晶体，以及一个或多个可裂解基团（C.G.）。一些实施例包括以不活性或较不活性形式制备的CSA化合物，该化合物能够在给予受试者、制备含有CSA组分的制药配方和/或暴露于生理条件下时转化为完全活性形式。制药组合物包括前药或药学上可接受的盐、立体异构体、溶剂化物或其多晶体以及一个或多个药学上可接受的辅料。需要治疗细菌感染的患者的治疗方法利用前药或药学上可接受的盐、立体异构体、溶剂化物、多晶体和/或本文所述的制药组合物。
• Toilet compositions
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0210842A2

  公开（公告）日：1987-02-04

  Transparent or translucent toilet compositions in bar form incorporating a smectite-type clay. The compositions are preferably milled toilet bars and demonstrate improved skin conditioning performance on oily skin types together with excellent bar appearance.

  透明或半透明的棒状洗浴用品组合物中含有一种埃克土类型的粘土。 这种组合物最好是磨碎的洗浴用品棒，对油性皮肤具有更好的皮肤调理性能，同时具有出色的棒状外观。
• Toilet composition and process
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0222525A2

  公开（公告）日：1987-05-20

  Toilet compositions in beta-phase bar form comprising 45% to 95% C8-24 fatty acid soap, 0% to 45% synthetic surfactant, and 0.01% to 5% of a water-soluble polymer. The compositions have improved lathering characteristics with excellent transparency/translucency.

  β-相棒状卫生间组合物，由 45% 至 95% 的 C8-24 脂肪酸皂、0% 至 45% 的合成表面活性剂和 0.01% 至 5% 的水溶性聚合物组成。 这种组合物具有更好的起泡特性和出色的透明度/半透明性。
• Toilet composition
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0311343A2

  公开（公告）日：1989-04-12

  Toilet compositions in beta-phase bar form comprising 45% to 90% C₈₋₂₄ fatty acid soap, 0.5% to 45% of ethoxylated nonionic surfactant, and 0.01% to 5% of a water-soluble polymer. The compositions have improved scum-control uncharacteristics with excellent mildness, smear, lathering and transparency/translucency.

  β-相棒状的卫生间组合物，包含 45% 至 90% 的 C₈₋₂₄脂肪酸皂、0.5% 至 45% 的乙氧基化非离子表面活性剂和 0.01% 至 5% 的水溶性聚合物。这种组合物具有更好的浮渣控制特性，同时具有极佳的温和性、涂抹性、起泡性和透明度/半透明性。
• Cationic steroidal antimicrobial prodrug compositions and uses thereof
  申请人：Savage Paul B.

  公开号：US10155788B2

  公开（公告）日：2018-12-18

  Prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, or polymorphs thereof include a pharmaceutically and/or diagnostically active cationic steroidal antimicrobial (hereinafter “CSA”) compound or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof, and one or more cleavable groups (C.G.). Some embodiments include a CSA compound prepared in an inactive or less active form and that is capable of conversion to a fully active form upon administration to a subject, upon preparation of a pharmaceutical formulation containing the CSA composition, and/or upon exposure to physiological conditions. Pharmaceutical compositions include the prodrug or pharmaceutically acceptable salt, stereoisomer, solvate, or polymorph thereof and one or more pharmaceutically acceptable excipients. Methods of treatment of bacterial infections in a patient in need utilize prodrugs or pharmaceutically acceptable salts, stereoisomers, solvates, polymorphs thereof and/or the pharmaceutical compositions described herein.

  原药或其药学上可接受的盐、立体异构体、溶解物或多晶型物包括具有药学和/或诊断活性的阳离子类固醇抗菌剂（以下简称 "CSA"）化合物或其药学上可接受的盐、立体异构体、溶解物或多晶型物，以及一个或多个可裂解基团（C.G.）。一些实施方案包括以无活性或活性较低的形式制备的 CSA 化合物，该化合物在给受试者用药、制备含有 CSA 组合物的药物制剂和/或暴露于生理条件下时能够转化为完全活性的形式。药物组合物包括原药或其药学上可接受的盐、立体异构体、溶解物或多晶型，以及一种或多种药学上可接受的赋形剂。利用原药或其药学上可接受的盐、立体异构体、溶解物、多晶型物和/或本文所述的药物组合物治疗有需要的患者的细菌感染的方法。